30
May
2024
14:00
BST
09:00
EDT
Webinar
Longitudinal Review of Cardiac Events With Acalabrutinib in the Treatment of Chronic Lymphocytic Leukaemia Using Data From Three Phase 3 Randomised Controlled Trials
-
Views:
688
-
Likes:
2
Overview
Join Dr Rupal O'Quinn (University of Pennsylvania, US), Prof Jennifer Brown (Dana-Farber Cancer Institute, US), Prof Daniel Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) in this cardio-oncology broadcast as they thoroughly examine cardiac outcomes with Acalabrutinib compared to active comparators in patients with and without cardiovascular disorders at baseline to evaluate the impact of Chronic Lymphocytic Leukaemia (CLL) therapies.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Faculty:
![Rupal O'Quinn](https://assets.radcliffecardiology.com/s3fs-public/author/2024-05/rupal%20o%27quinn.png?VersionId=3JdrPjAlLO5lioDY3RT7sk7HrFoqgYvA)
Rupal O'Quinn
![Jennifer Brown](https://assets.radcliffecardiology.com/s3fs-public/author/2024-05/Jennifer%20Brown_photo.jpg?VersionId=efO5tgtJIaysRHY2vhrEr2HnpYVb_XIJ)
Jennifer Brown
![Dan Lenihan](https://assets.radcliffecardiology.com/s3fs-public/author/2024-07/Daniel%20Lenihan.png?VersionId=eNSzsFtkYm9VPhMmP9Mf23jP7o3F.obe)
Dan Lenihan
![Joe Carver](https://assets.radcliffecardiology.com/s3fs-public/author/2024-07/Joe%20Carver.png?VersionId=fKbxyYDJPShJ9BqXyzrpZNYosbEPmBgA)
Joe Carver
This broadcast is supported by
![Sponsor](https://assets.radcliffecardiology.com/s3fs-public/webinar-sponsor/2024-05/IC-OS_1_2.png?VersionId=jDgubFj0iqjKmGrwWwIQlOCemdPCSybL)
Faculty Biographies
![Rupal O'Quinn](https://assets.radcliffecardiology.com/s3fs-public/author/2024-05/rupal%20o%27quinn.png?VersionId=3JdrPjAlLO5lioDY3RT7sk7HrFoqgYvA)
Rupal O'Quinn
Dr Rupal O'Quinn is an Associate Professor of Clinical Medicine at University of Pennsylvania, Philadelphia, US.
Dr O'Quinn has been the Director of Cardio-Oncology at Penn Presbyterian Medical Center since July 2020.
Dr O'Quinn specialises in the field of cardio-oncology, focusing their clinical work and research on patients with cardiovascular issues who have a history of cancer.
![Jennifer Brown](https://assets.radcliffecardiology.com/s3fs-public/author/2024-05/Jennifer%20Brown_photo.jpg?VersionId=efO5tgtJIaysRHY2vhrEr2HnpYVb_XIJ)
Jennifer Brown
Prof Jennifer Brown is Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, Massachusetts, US. She is also the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
Prof Brown's interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has played a key role in the clinical development of idelalisib, ibrutinib and zanubrutinib, leading to their regulatory approvals in CLL.
In 2014 she was the recipient of two awards from DFCI, the Clinical Innovation Award and the George Canellos Award. She has a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate.
![Dan Lenihan](https://assets.radcliffecardiology.com/s3fs-public/author/2024-07/Daniel%20Lenihan.png?VersionId=eNSzsFtkYm9VPhMmP9Mf23jP7o3F.obe)
Dan Lenihan
Dr Dan Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
![Joe Carver](https://assets.radcliffecardiology.com/s3fs-public/author/2024-07/Joe%20Carver.png?VersionId=fKbxyYDJPShJ9BqXyzrpZNYosbEPmBgA)
Joe Carver
Dr Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US. He is the Chief of Staff at the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.